Skip to main content
Erschienen in: Annals of Nuclear Medicine 1/2019

22.10.2018 | Original Article

The role of 13N-ammonia in the differential diagnosis of gliomas and brain inflammatory lesions

verfasst von: Chang Yi, Xinchong Shi, Xuezhen Zhang, Ganhua Luo, Bing Zhang, Xiangsong Zhang

Erschienen in: Annals of Nuclear Medicine | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Abstract

Objective

To investigate the utility of 13N-ammonia PET/CT imaging in the differential diagnosis of gliomas and brain inflammations.

Methods

13N-ammonia PET/CT imaging data of 77 patients with gliomas and 34 patients with brain inflammations were retrospectively analyzed. No patients received any treatment before 13N-ammonia imaging. All the patients were diagnosed by stereotactic biopsy or clinical follow-up. Visual and semi-quantitative analysis was performed to analyze the results of 13N-ammonia imaging. Finally, the uptake ratios of each lesion were calculated and its differences among different groups were tested with one-way ANOVA.

Results

29.4% inflammations, 51.6% low-grade gliomas and 91.3% high-grade gliomas were positive by visual analysis in 13N-ammonia imaging. The sensitivity, specificity and accuracy for the diagnosis of gliomas were 75.3%, 55.8% and 67.8%, respectively. As for semi-quantitative analysis, the T/G ratios of inflammatory lesions, low-grade gliomas and high-grade gliomas were 0.88 ± 0.24, 1.04 ± 0.43 and 1.43 ± 0.49, respectively. One-way ANOVA revealed that the T/G ratios of high-grade gliomas were significantly higher than those of low-grade gliomas and inflammations (P < 0.05), but there was no statistical difference between low-grade gliomas and inflammations (P = 0.118). Among the inflammatory lesions, T/G ratios were not statistically different between infectious and demyelinating lesions (P > 0.05). ROC curve analysis showed that the optimal cut-off value of T/G ratio in distinguishing gliomas from inflammations was 1.21 with the AUC 0.78. The sensitivity, specificity, accuracy, PPV and NPV were 52.9%, 94.4%, 65.3%, 95.7% and 45.9%, respectively. ROC curve analysis showed that the optimal cut-off value of T/G ratio in distinguishing high-grade gliomas from low-grade gliomas was 1.06 with the AUC 0.78. The sensitivity, specificity, accuracy, PPV and NPV were 81.5%, 67.7%, 76.5%, 81.5% and 67.7%, respectively. ROC curve analysis showed that the optimal cut-off value of T/G ratio in distinguishing high-grade gliomas from low-grade gliomas and inflammations was 1.19 with the AUC 0.84. The sensitivity, specificity, accuracy, PPV and NPV were 70.4%, 85.1%, 78.5%, 79.2% and 78.1%, respectively.

Conclusions

13N-ammonia imaging is effective in distinguishing high-grade gliomas from low-grade gliomas and inflammations, but its role in the differential diagnosis of low-grade gliomas and brain inflammatory lesions is limited, and the accuracy needs to be improved.
Literatur
1.
Zurück zum Zitat Hervey-Jumper SL, Berger MS. Maximizing safe resection of low- and high-grade glioma. J Neurooncol. 2016;130:269–82.CrossRefPubMed Hervey-Jumper SL, Berger MS. Maximizing safe resection of low- and high-grade glioma. J Neurooncol. 2016;130:269–82.CrossRefPubMed
2.
Zurück zum Zitat Hutterer M, Hattingen E, Palm C, Proescholdt MA, Hau P. Current standards and new concepts in MRI and PET response assessment of antiangiogenic therapies in high-grade glioma patients. Neuro Oncol. 2015;17:784–800.CrossRefPubMed Hutterer M, Hattingen E, Palm C, Proescholdt MA, Hau P. Current standards and new concepts in MRI and PET response assessment of antiangiogenic therapies in high-grade glioma patients. Neuro Oncol. 2015;17:784–800.CrossRefPubMed
3.
Zurück zum Zitat Khan MN, Sharma AM, Pitz M, Loewen SK, Quon H, Poulin A, et al. High-grade glioma management and response assessment-recent advances and current challenges. Curr Oncol. 2016;23:e383–91.CrossRefPubMedPubMedCentral Khan MN, Sharma AM, Pitz M, Loewen SK, Quon H, Poulin A, et al. High-grade glioma management and response assessment-recent advances and current challenges. Curr Oncol. 2016;23:e383–91.CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Knudsen-Baas KM, Moen G, Fluge O, Storstein A. Pseudoprogression in high-grade glioma. Acta Neurol Scand Suppl. 2013;127(196):31–37.CrossRef Knudsen-Baas KM, Moen G, Fluge O, Storstein A. Pseudoprogression in high-grade glioma. Acta Neurol Scand Suppl. 2013;127(196):31–37.CrossRef
5.
Zurück zum Zitat Galldiks N, Langen KJ, Pope WB. From the clinician’s point of view—what is the status quo of positron emission tomography in patients with brain tumors? Neuro Oncol. 2015;17:1434–44.CrossRefPubMedPubMedCentral Galldiks N, Langen KJ, Pope WB. From the clinician’s point of view—what is the status quo of positron emission tomography in patients with brain tumors? Neuro Oncol. 2015;17:1434–44.CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Puttick S, Bell C, Dowson N, Rose S, Fay M. PET, MRI, and simultaneous PET/MRI in the development of diagnostic and therapeutic strategies for glioma. Drug Discov Today. 2015;20:306–17.CrossRefPubMed Puttick S, Bell C, Dowson N, Rose S, Fay M. PET, MRI, and simultaneous PET/MRI in the development of diagnostic and therapeutic strategies for glioma. Drug Discov Today. 2015;20:306–17.CrossRefPubMed
7.
Zurück zum Zitat Nihashi T, Dahabreh IJ, Terasawa T. Diagnostic accuracy of PET for recurrent glioma diagnosis: a meta-analysis. AJNR Am J Neuroradiol. 2013;34:944–50. (S941–911).CrossRefPubMed Nihashi T, Dahabreh IJ, Terasawa T. Diagnostic accuracy of PET for recurrent glioma diagnosis: a meta-analysis. AJNR Am J Neuroradiol. 2013;34:944–50. (S941–911).CrossRefPubMed
8.
Zurück zum Zitat Kawai N, Okauchi M, Miyake K, Sasakawa Y, Yamamoto Y, Nishiyama Y, et al. 11C-methionine positron emission tomography in nontumorous brain lesions. No ShinkeiGeka. 2010;38(11):985–95. Kawai N, Okauchi M, Miyake K, Sasakawa Y, Yamamoto Y, Nishiyama Y, et al. 11C-methionine positron emission tomography in nontumorous brain lesions. No ShinkeiGeka. 2010;38(11):985–95.
9.
Zurück zum Zitat Demetriades AK, Almeida AC, Bhangoo RS, Barrington SF. Applications of positron emission tomography in neuro-oncology: a clinical approach. Surgeon. 2014;12:148–57.CrossRefPubMed Demetriades AK, Almeida AC, Bhangoo RS, Barrington SF. Applications of positron emission tomography in neuro-oncology: a clinical approach. Surgeon. 2014;12:148–57.CrossRefPubMed
10.
Zurück zum Zitat Galldiks N, Kracht LW, Burghaus L, Thomas A, Jacobs AH, Heiss WD, et al. Use of 11C-methionine PET to monitor the effects of temozolomide chemotherapy in malignant gliomas. Eur J Nucl Med Mol Imaging. 2006;33:516–24.CrossRefPubMed Galldiks N, Kracht LW, Burghaus L, Thomas A, Jacobs AH, Heiss WD, et al. Use of 11C-methionine PET to monitor the effects of temozolomide chemotherapy in malignant gliomas. Eur J Nucl Med Mol Imaging. 2006;33:516–24.CrossRefPubMed
11.
Zurück zum Zitat Rapp M, Floeth FW, Felsberg J, Steiger HJ, Sabel M, Langen KJ, et al. Clinical value of O-(2-[(18)F]-fluoroethyl)-l-tyrosine positron emission tomography in patients with low-grade glioma. Neurosurg Focus. 2013;34:E3.CrossRefPubMed Rapp M, Floeth FW, Felsberg J, Steiger HJ, Sabel M, Langen KJ, et al. Clinical value of O-(2-[(18)F]-fluoroethyl)-l-tyrosine positron emission tomography in patients with low-grade glioma. Neurosurg Focus. 2013;34:E3.CrossRefPubMed
12.
Zurück zum Zitat Shi X, Liu Y, Zhang X, Yi C, Wang X, Chen Z, et al. The comparison of 13 N-ammonia and 18F-FDG in the evaluation of untreated gliomas. Clin Nucl Med. 2013;38:522–6.CrossRefPubMed Shi X, Liu Y, Zhang X, Yi C, Wang X, Chen Z, et al. The comparison of 13 N-ammonia and 18F-FDG in the evaluation of untreated gliomas. Clin Nucl Med. 2013;38:522–6.CrossRefPubMed
13.
Zurück zum Zitat Shi X, Yi C, Wang X, Zhang B, Chen Z, Tang G, et al. 13 N-ammonia combined with 18F-FDG could discriminate between necrotic high-grade gliomas and brain abscess. Clin Nucl Med. 2015;40:195–9.CrossRefPubMed Shi X, Yi C, Wang X, Zhang B, Chen Z, Tang G, et al. 13 N-ammonia combined with 18F-FDG could discriminate between necrotic high-grade gliomas and brain abscess. Clin Nucl Med. 2015;40:195–9.CrossRefPubMed
14.
Zurück zum Zitat Xiangsong Z, Changhong L, Weian C, Dong Z. PET Imaging of cerebral astrocytoma with 13 N-ammonia. J Neurooncol. 2006;78:145–51.CrossRefPubMed Xiangsong Z, Changhong L, Weian C, Dong Z. PET Imaging of cerebral astrocytoma with 13 N-ammonia. J Neurooncol. 2006;78:145–51.CrossRefPubMed
15.
Zurück zum Zitat Xiangsong Z, Xingchong S, Chang Y, Xiaoyan W, Zhifeng C. 13 N-ammonia versus F-18 FDG in detection of intracranial meningioma: initial report. Clin Nucl Med. 2011;36:1003–6.CrossRefPubMed Xiangsong Z, Xingchong S, Chang Y, Xiaoyan W, Zhifeng C. 13 N-ammonia versus F-18 FDG in detection of intracranial meningioma: initial report. Clin Nucl Med. 2011;36:1003–6.CrossRefPubMed
16.
Zurück zum Zitat Aghi MK, Nahed BV, Sloan AE, Ryken TC, Kalkanis SN, Olson JJ. The role of surgery in the management of patients with diffuse low grade glioma: a systematic review and evidence-based clinical practice guideline. J Neurooncol. 2015;125:503–30.CrossRefPubMed Aghi MK, Nahed BV, Sloan AE, Ryken TC, Kalkanis SN, Olson JJ. The role of surgery in the management of patients with diffuse low grade glioma: a systematic review and evidence-based clinical practice guideline. J Neurooncol. 2015;125:503–30.CrossRefPubMed
17.
Zurück zum Zitat Hadjipanayis CG, Widhalm G, Stummer W. What is the surgical benefit of utilizing 5-aminolevulinic acid for fluorescence-guided surgery of malignant gliomas? Neurosurgery. 2015;77:663–73.CrossRefPubMedPubMedCentral Hadjipanayis CG, Widhalm G, Stummer W. What is the surgical benefit of utilizing 5-aminolevulinic acid for fluorescence-guided surgery of malignant gliomas? Neurosurgery. 2015;77:663–73.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Cooper AJ. 13N as a tracer for studying glutamate metabolism. Neurochem Int. 2011;59:456–64.CrossRefPubMed Cooper AJ. 13N as a tracer for studying glutamate metabolism. Neurochem Int. 2011;59:456–64.CrossRefPubMed
19.
Zurück zum Zitat Keiding S, Sorensen M, Bender D, Munk OL, Ott P, Vilstrup H. Brain metabolism of 13 N-ammonia during acute hepatic encephalopathy in cirrhosis measured by positron emission tomography. Hepatology. 2006;43:42–50.CrossRefPubMed Keiding S, Sorensen M, Bender D, Munk OL, Ott P, Vilstrup H. Brain metabolism of 13 N-ammonia during acute hepatic encephalopathy in cirrhosis measured by positron emission tomography. Hepatology. 2006;43:42–50.CrossRefPubMed
20.
Zurück zum Zitat Momosaki S, Ito M, Tonomura M, Abe K. Assessment of glutamine synthetase activity by [13N]ammonia uptake in living rat brain. Synapse. 2015;69:26–32.CrossRefPubMed Momosaki S, Ito M, Tonomura M, Abe K. Assessment of glutamine synthetase activity by [13N]ammonia uptake in living rat brain. Synapse. 2015;69:26–32.CrossRefPubMed
21.
Zurück zum Zitat Hu LS, Eschbacher JM, Dueck AC, Heiserman JE, Liu S, Karis JP, et al. Correlations between perfusion MR imaging cerebral blood volume, microvessel quantification, and clinical outcome using stereotactic analysis in recurrent high-grade glioma. AJNR Am J Neuroradiol. 2012;33:69–76.CrossRefPubMed Hu LS, Eschbacher JM, Dueck AC, Heiserman JE, Liu S, Karis JP, et al. Correlations between perfusion MR imaging cerebral blood volume, microvessel quantification, and clinical outcome using stereotactic analysis in recurrent high-grade glioma. AJNR Am J Neuroradiol. 2012;33:69–76.CrossRefPubMed
22.
Zurück zum Zitat Vajkoczy P, Schilling L, Ullrich A, Schmiedek P, Menger MD. Characterization of angiogenesis and microcirculation of high-grade glioma: an intravital multifluorescence microscopic approach in the athymic nude mouse. J Cereb Blood Flow Metab. 1998;18:510–20.CrossRefPubMed Vajkoczy P, Schilling L, Ullrich A, Schmiedek P, Menger MD. Characterization of angiogenesis and microcirculation of high-grade glioma: an intravital multifluorescence microscopic approach in the athymic nude mouse. J Cereb Blood Flow Metab. 1998;18:510–20.CrossRefPubMed
23.
Zurück zum Zitat Levashova Z, Backer M, Backer JM, Blankenberg FG. Imaging vascular endothelial growth factor (VEGF) receptors in turpentine-induced sterile thigh abscesses with radiolabeled single-chain VEGF. J Nucl Med. 2009;50:2058–63.CrossRefPubMed Levashova Z, Backer M, Backer JM, Blankenberg FG. Imaging vascular endothelial growth factor (VEGF) receptors in turpentine-induced sterile thigh abscesses with radiolabeled single-chain VEGF. J Nucl Med. 2009;50:2058–63.CrossRefPubMed
24.
Zurück zum Zitat Szade A, Grochot-Przeczek A, Florczyk U, Jozkowicz A, Dulak J. Cellular and molecular mechanisms of inflammation-induced angiogenesis. IUBMB Life. 2015;67:145–59.CrossRefPubMed Szade A, Grochot-Przeczek A, Florczyk U, Jozkowicz A, Dulak J. Cellular and molecular mechanisms of inflammation-induced angiogenesis. IUBMB Life. 2015;67:145–59.CrossRefPubMed
25.
Zurück zum Zitat Bode JG, Peters-Regehr T, Kubitz R, Haussinger D. Expression of glutamine synthetase in macrophages. J Histochem Cytochem. 2000;48:415–22.CrossRefPubMed Bode JG, Peters-Regehr T, Kubitz R, Haussinger D. Expression of glutamine synthetase in macrophages. J Histochem Cytochem. 2000;48:415–22.CrossRefPubMed
26.
Zurück zum Zitat Gras G, Porcheray F, Samah B, Leone C. The glutamate–glutamine cycle as an inducible, protective face of macrophage activation. J Leukoc Biol. 2006;80:1067–75.CrossRefPubMed Gras G, Porcheray F, Samah B, Leone C. The glutamate–glutamine cycle as an inducible, protective face of macrophage activation. J Leukoc Biol. 2006;80:1067–75.CrossRefPubMed
27.
Zurück zum Zitat Abrigo JM, Fountain DM, Provenzale JM, Law EK, Kwong JS, Hart MG, et al. Magnetic resonance perfusion for differentiating low-grade from high-grade gliomas at first presentation. Cochrane Datab Syst Rev. 2018;1:CD011551. Abrigo JM, Fountain DM, Provenzale JM, Law EK, Kwong JS, Hart MG, et al. Magnetic resonance perfusion for differentiating low-grade from high-grade gliomas at first presentation. Cochrane Datab Syst Rev. 2018;1:CD011551.
29.
Zurück zum Zitat Akimoto J. Immunohistochemical study of glutamine synthetase expression in normal human brain and intracranial tumors. No To Shinkei. 1993;45:362–8.PubMed Akimoto J. Immunohistochemical study of glutamine synthetase expression in normal human brain and intracranial tumors. No To Shinkei. 1993;45:362–8.PubMed
30.
Zurück zum Zitat Li D, Zhao X, Zhang L, Li F, Ji N, Gao Z, et al. (68)Ga-PRGD2 PET/CT in the evaluation of glioma: a prospective study. Mol Pharm. 2014;11:3923–9.CrossRefPubMedPubMedCentral Li D, Zhao X, Zhang L, Li F, Ji N, Gao Z, et al. (68)Ga-PRGD2 PET/CT in the evaluation of glioma: a prospective study. Mol Pharm. 2014;11:3923–9.CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Heiss WD, Wienhard K, Wagner R, Lanfermann H, Thiel A, Herholz K, et al. F-Dopa as an amino acid tracer to detect brain tumors. J Nucl Med. 1996;37:1180–2.PubMed Heiss WD, Wienhard K, Wagner R, Lanfermann H, Thiel A, Herholz K, et al. F-Dopa as an amino acid tracer to detect brain tumors. J Nucl Med. 1996;37:1180–2.PubMed
32.
Zurück zum Zitat Jansen NL, Suchorska B, Wenter V, Eigenbrod S, Schmid-Tannwald C, Zwergal A, et al. Dynamic 18F-FET PET in newly diagnosed astrocytic low-grade glioma identifies high-risk patients. J Nucl Med. 2014;55:198–203.CrossRefPubMed Jansen NL, Suchorska B, Wenter V, Eigenbrod S, Schmid-Tannwald C, Zwergal A, et al. Dynamic 18F-FET PET in newly diagnosed astrocytic low-grade glioma identifies high-risk patients. J Nucl Med. 2014;55:198–203.CrossRefPubMed
33.
Zurück zum Zitat Sala Q, Metellus P, Taieb D, Kaphan E, Figarella-Branger D, Guedj E. 18F-DOPA, a clinically available PET tracer to study brain inflammation? Clin Nucl Med. 2014;39:e283–5.CrossRefPubMed Sala Q, Metellus P, Taieb D, Kaphan E, Figarella-Branger D, Guedj E. 18F-DOPA, a clinically available PET tracer to study brain inflammation? Clin Nucl Med. 2014;39:e283–5.CrossRefPubMed
34.
Zurück zum Zitat McCormick D, McQuaid S, McCusker C, Allen IV. A study of glutamine synthetase in normal human brain and intracranial tumours. Neuropathol Appl Neurobiol. 1990;16(3):205–11.CrossRefPubMed McCormick D, McQuaid S, McCusker C, Allen IV. A study of glutamine synthetase in normal human brain and intracranial tumours. Neuropathol Appl Neurobiol. 1990;16(3):205–11.CrossRefPubMed
35.
Zurück zum Zitat Shi X, Zhang X, Yi C, Wang X, Chen Z, Zhang B. The combination of 13 N-ammonia and 18F-FDG in predicting primary central nervous system lymphomas in immunocompetent patients. Clin Nucl Med. 2013;38:98–102.CrossRefPubMed Shi X, Zhang X, Yi C, Wang X, Chen Z, Zhang B. The combination of 13 N-ammonia and 18F-FDG in predicting primary central nervous system lymphomas in immunocompetent patients. Clin Nucl Med. 2013;38:98–102.CrossRefPubMed
Metadaten
Titel
The role of 13N-ammonia in the differential diagnosis of gliomas and brain inflammatory lesions
verfasst von
Chang Yi
Xinchong Shi
Xuezhen Zhang
Ganhua Luo
Bing Zhang
Xiangsong Zhang
Publikationsdatum
22.10.2018
Verlag
Springer Singapore
Erschienen in
Annals of Nuclear Medicine / Ausgabe 1/2019
Print ISSN: 0914-7187
Elektronische ISSN: 1864-6433
DOI
https://doi.org/10.1007/s12149-018-1308-2

Weitere Artikel der Ausgabe 1/2019

Annals of Nuclear Medicine 1/2019 Zur Ausgabe